HER2 FPBMC Therapy in the AM006 Phase 1/2 Trial for Metastatic Prostate Cancer

The AM006 clinical trial, tests HER2 FPBMC anti-CD3 x anti-HER2 bispecific antibody (HER2Bi)-armed activated T cells,in patients with HER2-positive metastatic prostate and breast cancer. For prostate cancer patients, this targets the 20-30% of metastatic cases overexpressing HER2, offering a fresh immune-based option after standard therapies fail.

HER2 FPBMC starts with a simple blood draw to harvest the patient’s own T cells, the immune system’s key attackers. In the lab, these cells get activated with anti-CD3 and armed with HER2Bi, a dual-headed antibody: one end grips the T cell’s CD3 receptor to energize it, the other binds HER2 on tumor cells. Once infused back, the armed T cells seek out and destroy HER2-expressing tumors through direct contact, bypassing MHC restrictions that limit other therapies.

This delivers a double hit. The armed cells unleash perforin and granzymes for rapid tumor lysis, with lab data on hormone-resistant prostate lines like PC-3 showing 2-3x greater killing than unarmed T cells. They also release Th1 cytokines, interferon-gamma, TNF-alpha, GM-CSF, that amplify the response, recruiting more immune cells and creating lasting anti-tumor memory.

As a Phase 1/2 trial, the initial focus is safety and dosing. Prior studies in prostate cancer reported manageable side effects, mainly cytokine release syndrome like flu symptoms, with no dose-limiting toxicities at tested levels. Early signals included stable disease, PSA declines, and tumor shrinkage on scans in some mCRPC cases.

In prostate cancer, this fills a key gap for HER2-positive tumors resistant to ADT, taxanes, or PARP inhibitors. Preclinical mouse models showed tumor regression without off-target damage, and human data confirmed T cell persistence for weeks post-infusion, supporting repeat dosing.

Clinical trial.